Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Nov 9, 2023 | Press Releases

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor...

Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas

Nov 9, 2023 | Press Releases

MARLBOROUGH, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor...

Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control

Nov 3, 2023 | Press Releases

Intratumoral injection of INTASYL self-delivering RNAi compound targeting CTLA-4 (27790) in combination with systemic anti-PD-1 antibody therapy offers a novel approach to combination Immune Checkpoint Inhibition (ICI) therapiesMARLBOROUGH, Mass., Nov. 03, 2023 (GLOBE...

Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 12, 2023 | Press Releases

MARLBOROUGH, Mass., Oct. 12, 2023 (GLOBE NEWSWIRE) — Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ RNAi platform technology is designed to make immune cells more effective in killing tumor...

Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894

Oct 11, 2023 | Press Releases

–Preclinical data shows melanoma cells treated with PH-894 makes them more recognizable to immune cells, increasing potential for elimination –Preclinical data demonstrates the effectiveness of PH-894 as an antitumor cytotoxic agent (directly killing tumor...